Form 4 for RGNX REGENXBIO Inc.
Accepted 2025-09-12 00:00:00 ET · period of report 2025-09-10 · accession 0001562180-25-006194 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2025-09-12 | 2025-09-10 | RGNX | Simpson Curran | CEO, Dir | S - Sale | $10.02 | -7,734 | 244.6K | -3% | -$77.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-09-10 | S | D | 7,734 | $10.02 | 244,597 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $10.00 to $10.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. |